

DAFTAR PUSTAKA

1. Cutsem van. E et al, 2016. ESMO Consensus Guidelines For The Management Of Patients With Metastatic Colorectal Cancer. *Annals of Oncology* 27: 1386–1422, 2016 doi:10.1093/annonc/mdw235
2. Aran V, Victorino AP, Thuler LC, Ferreira CG. 2016. Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. Elsevier.
3. Weng W, Feng J, Qin H, Ma Y, and Goel A. 2015. An Update on MiRNAs as Biological and Clinical Determinants in Colorectal Cancer: a bench-to-bedside approach. *Future Oncology* 11(12): 1791–1808.
4. Ferlay, J, Soerjomataram I, Dikshit R. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: pp. E359E386
5. Peery A, Dellon ES, Lund J, et al. 2012. Burden of gastrointestinal disease in the United States: 2012 Update. *Gastroenterology* 143: 1179-1187
6. Bailey CE, Hu CY, You YN, et al. 2015. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. *JAMA Surg* 150: 17-22
7. Burt R, and Neklason DW. 2005. Genetic testing for inherited colon cancer. *Gastroenterology* 128: 1696-1716
8. Fearon ER. 2011. Molecular genetics of colorectal cancer. *Ann Rev Pathol* 6: 470-507
9. Schneider BL, Kulesz-Martin M. Destructive cycles. 2004. The Role of Genomic Instability and Adaptation in Carcinogenesis. *Carcinogenesis* 25:2033-2044
10. Zhu B, Sun Y, Qi L, Zhong R, and Miao X. 2015. Dietary legume consumption reduces risk of colorectal cancer: evidence from a meta-analysis of cohort studies. *Sci Rep* 5: 8797
11. Herrinton LJ, Liu L, Levin TR, et al. 2012. Incidence and Mortality of Colorectal Adenocarcinoma in Persons with Inflammatory Bowel Disease from 1998 to 2010. *Gastroenterology* 143:382-389
12. Gonzalez CA and Riboli E. 2010. diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur J Cancer* 46: 2555-2562
13. Aalok Kumar HFK, Lim HJ, Renouf DJ, Woods R, Speers C, and Cheung Wy. 2012. Adjuvant chemotherapy (AC) use and outcomes in stage II colon cancer (CC) with and without poor prognostic features. *J Clin Oncol* 30

14. Andre T, Boni, Navarro M, et al. 2009 improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol* 27: 3109-3116
15. Tournigand C, Andre T, Bonnetain F, et al. 2012. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. *J Clin Oncol* 30: 3353-3360
16. Sargent DJ, Yothers G, et al. 2014. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. *J Clin Oncol* 32: 5
17. Bartel DP. 2009. microRNA: target recognition and regulatory functions. *Cell* 136:215-233
18. Raisch J, Darfeuille-Michaud A, Nguyen HT. 2013. role of microRNAs in the immune system, inflammation and cancer. *World Journal Gastroenterology* 19:2985-2996
19. Altomare DF, Di Lena M, Giuratrabocchetta S. 2012. microRNA: future perspective in colorectal cancer. *Colorectal Dis* 14:133-134
20. Fearon ER, Volgestein B. 1990. A genetic model for colorectal tumorigenesis. *Cell* 61:759-767
21. Ahmed FE, Jeffries CD, Vos PW, et al. 2009. diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. *Cancer Genomics Proteomics* 6:281-295
22. Cheng H, Zhang I, Cogdell DE, et al. 2011. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLoS One* 6:e17745
23. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. 2010. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *International Journal of Cancer* 127:118-126
24. Pu XX, Huang DI, Guo HQ, et al. 2010. Circulating MiR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. *Journal of Gastroenterology and Hepatology* 25:1674-1680
25. Ng EK, Iguchi H, Ochiya T. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer Science* 101:2087-2092
26. Yu HW, Sze DM, Cho WC. 2013. MicroRNAs Involved in Anti-Tumour Immunity. *Int J Mol Sci* 14: 5587-5607

27. Yu H, Kortylewski M, Pardoll D. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol* 7: 41-51
28. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB. 2013. MiR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. *Cancer Res* 73: 3913-3926
29. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC. 2008. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA* 299: 425-436
30. Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M. 2014. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. *World J. Gastroenterol* 20, 11727–11735
31. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. 2014 Serum MiR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. *Ann. Surg* 259, 735–743.
32. Hansen TF, Christensen RD, Andersen RF, Sørensen FB, Johnsson A, Jakobsen A. 2013. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. *Br. J. Cancer* 109, 1243–1251
33. Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, Fu X, Palazzo JP, He X, Chen Z, Yang H. 2012. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. *Cancer Epidemiol. Biomark. Prev.* 21, 217–227.
34. Compton C, Tanabe K. 2015. Pathology and Prognostic Determinants of CRC. UpToDate: Waltham, MA, USA,
35. Clark J, Grothey A, Goldberg R. 2015. Systemic Chemotherapy for Nonoperable Metastatic Colorectal Cancer: Treatment Recommendations. UpToDate: Waltham, MA, USA, 2015
36. Bader A, Lammers P. The Therapeutic Potential of microRNAs. *Innov. Pharm. Technol.* Available online: <http://biology.westfield.ma.edu/biol104-501/sites/default/files/Therapeutic-Potential-microRNAs.pdf> (accessed on 15 July 2015).
37. Thomas J, Ohtsuka M, Pichler M, Ling H. 2015. MicroRNAs: Clinical Relevance in Colorectal Cancer. *International Journal of Molecular Science* 16: 28063-28076

38. Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. 2012. Molecular profile of colorectal cancer in Indonesia: is there another pathway? *Gastroenterology and Hepatology From Bed to Bench* 5(2): 71-78
39. Wang L, Qian L, Li X, Yan J. 2014. MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. *Mol Med Rep* 10(1): 473-478
40. Kokki I, Papan A, Campbell H, Theodoratou E, 2013, Estimating the incidence of colorectal cancer in South East Asia. *Croat Med J*, 54: 532-540.
41. Kim JW, Shin MK, Kim BC, 2015, Clinicopathologic impacts of poorly differentiated cluster-based grading system in colorectal carcinoma. *J Korean Med Sci*, 30:16-23.